The Biotech Startups Podcast
🧬 "Be On It”: High-Stakes Deals & Building World-Class Teams | Sujal Patel (Part 3/4)
March 9, 2026
In this episode of The Biotech Startups Podcast, we dive into part three of Founder and CEO at Nautilus Biotechnology, Sujal Patel’s story—zooming in on the high-stakes path to Isilon’s acquisition by EMC and what it really feels like to negotiate while your company, your board, and the market clock are all in motion. Sujal walks through how the “strategic partnership” conversations revealed themselves as acquisition positioning, why EMC’s approach felt unusually aggressive and old-school, and how a deal can appear to die on the finish line—only to roar back to life under intense time pressure. Sujal also shares the tactical and emotional reality of price negotiation, from holding the line when an acquirer tries to anchor you, to staying disciplined in your responses, to making decisions fast when the range tightens and leaks force a deadline. From there, the conversation expands into what happens after the announcement: the commitments he made to EMC about scaling the business, the organizational decisions that protected long-term value, and the personal calculus behind eventually leaving—even when bigger roles were on the table.
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.

As a TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.

“As an entrepreneur, you have to be on it—taking advantage of every opportunity to build relationships and get the best people on your team.”

In this episode of The Biotech Startups Podcast, we dive into part three of Founder and CEO at Nautilus Biotechnology, Sujal Patel’s story—zooming in on the high-stakes path to Isilon’s acquisition by EMC and what it really feels like to negotiate while your company, your board, and the market clock are all in motion. Sujal walks through how the “strategic partnership” conversations revealed themselves as acquisition positioning, why EMC’s approach felt unusually aggressive and old-school, and how a deal can appear to die on the finish line—only to roar back to life under intense time pressure.

Sujal also shares the tactical and emotional reality of price negotiation, from holding the line when an acquirer tries to anchor you, to staying disciplined in your responses, to making decisions fast when the range tightens and leaks force a deadline. From there, the conversation expands into what happens after the announcement: the commitments he made to EMC about scaling the business, the organizational decisions that protected long-term value, and the personal calculus behind eventually leaving—even when bigger roles were on the table.


Key topics covered:


If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.

Subscribe to the Podcast:
Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4
Youtube: https://www.youtube.com/@thebiotechstartupspodcast 
Website: https://www.thebiotechstartupspodcast.com/ 

Find our guest, Sujal Patel at these links: 
LinkedIn: https://www.linkedin.com/in/patelsujal/
Website: https://www.nautilus.bio/
 
Find our host, Jon Chee, at these links: 
LinkedIn: https://www.linkedin.com/in/jonchee

Learn more about Excedr:
LinkedIn: https://www.linkedin.com/company/excedr/ 
Website: https://www.excedr.com

Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Website: https://flow.page/kyojin 

Resources & Articles:
Mass Spectrometry-Based Clinical Proteomics https://pubmed.ncbi.nlm.nih.gov/12831324/
​Fueling the Future with Mass Spectrometry-Based Proteomics https://www.americanlaboratory.com/607446-Fueling-the-Future-with-Mass-Spectrometry-based-Proteomics/
​The Founder’s Guide to Product-Market Fit
https://innovatemap.com/resource/the-founders-guide-to-product-market-fit
​Product Market Fit: Ultimate Guide for Startup Founders
https://foundersnetwork.com/product-market-fit/
​Go-to-Market Fit: Founders’ Guide to Crossing the Chasm
https://www.11.vc/crossing-the-chasm-the-journey-from-pmf-to-gtm/
Marketing & Sales Strategies for Early-Stage Biotechs
https://www.excedr.com/blog/marketing-sales-strategies-for-biotechs

Companies, Universities, & People mentioned:
EMC (now Dell EMC):https://www.delltechnologies.com/en-us/storage/index.htm
​NetApp: https://www.netapp.com

Pat Gelsinger https://www.linkedin.com/in/patgelsinger/ 
​Harry You https://spacconference.com/speaker/harry-you
​Parag Mallick https://www.linkedin.com/in/parag/ 
​Michael Dell https://www.linkedin.com/in/mdell/ 
​
Timestamps: 
00:00 Intro
01:47 EMC's Unexpected Voicemail and the OEM Pretense
04:35 Pat Gelsinger's Dinner and Harry You's Surprise Appearance
07:06 The $25 Offer, Bidding Wars, and Walking Away from the Deal
09:57 The Friday Fax: A Fully Executed Merger Agreement at $32.50
11:15 Saturday Negotiation and How $33.85 Became the Final Price
13:00 Post-Acquisition: Running the Division and Reporting to Pat Gelsinger
16:07 Knowing When It Was Time to Leave EMC
18:48 Key Lessons from Isilon: Developing People and Hiring Right
23:15 Redefining Product-Market Fit Beyond the Traditional Definition
26:18 Four Years Off: Investing, Board Seats, and Getting Back in the Ring
29:07 Founding Nautilus: Meeting Parag and the Proteomics Vision
33:47 Outro

The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.